Treatment
Cell clinical trials
We’re tracking 5,686 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT05003960RecruitingPhase 1
Testing an IV stem cell treatment for autism safety
This trial tests whether an IV infusion of lab-made donor stem cells is safe for people with autism. It mainly looks at side effects and whether the treatment can be given without causing harm.
St John'sAges Any age - NCT05003947RecruitingPhase 1
Stem cell infusion for Crohn’s or ulcerative colitis safety
This Phase 1 trial tests whether an IV infusion of donated (allogeneic) stem cells is safe in people with Crohn’s disease or ulcerative colitis. It focuses mainly on safety and tolerability, and it may offer a new treatment approach if you qualify.
St John'sAges Any age - NCT05003934RecruitingPhase 1
IV stem cell treatment safety study for rheumatoid arthritis
This Phase 1 trial tests how safe an intravenous (through a vein) stem cell product is for people with rheumatoid arthritis. It is mainly looking for side effects and safety rather than proving it works yet.
St John'sAges Any age - NCT05011487RecruitingPhase 2
Before-surgery osimertinib plus chemotherapy for EGFR lung cancer
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
Guangzhou, GuangdongAges 18–75 - NCT05016817RecruitingPhase 1
Testing an IV stem cell treatment for idiopathic pulmonary fibrosis
This Phase 1 study tests whether an IV infusion of stem cells from donated umbilical cord tissue is safe for people with idiopathic pulmonary fibrosis. It focuses mainly on safety and tolerability, and it may help by offering a new treatment approach if the cells are safe for you.
St John'sAges Any age - NCT05016804RecruitingPhase 1
Umbilical cord stem cell infusion trial for systemic sclerosis
This early safety study tests whether an intravenous (through a vein) stem cell product made from donated umbilical cord cells is safe for people with systemic sclerosis. If you join, the goal is to see how your body tolerates the treatment and monitor for side effects.
St John'sAges Any age - NCT05018845RecruitingPhase 1
Testing a donated stem cell treatment for chronic kidney disease
This early study (Phase 1) tests whether an intravenously given, donated stem cell product is safe for people with chronic kidney disease. It mainly looks at side effects and whether the treatment can be given without harming you.
St John'sAges Any age - NCT05018520RecruitingPhase 3
Two chemotherapy schedules for newly diagnosed low-risk DLBCL
This trial compares two different shortened treatment schedules of R-CHOP to see which one is safer and works better for people with low-risk diffuse large B-cell lymphoma (DLBCL). It aims to reduce risk from treatment while maintaining strong cancer control after an initial response.
Shanghai, Shanghai MunicipalityAges 14–75 - NCT05018819RecruitingPhase 1
IV stem cell treatment for cerebral palsy safety
This trial tests whether an IV infusion of lab-grown stem cells from donated umbilical cord is safe for people with cerebral palsy. It mainly focuses on side effects and safety rather than proving it works.
St John'sAges Any age - NCT05022446Recruiting
Survey study on how COVID-19 affected lung procedures
This study is a survey sent to U.S. lung doctors to understand how COVID-19 changed the way certain lung procedures are done. Your answers could help improve future care and planning during respiratory outbreaks.
Houston, TexasAges Any age - NCT05025878Recruiting
Study tracking sugar and immune cells in ovarian cancer fluid
This study uses a trace amount of glucose (a type of sugar) to see how tumor cells and immune cells behave inside the fluid that collects with ovarian cancer (ascites). It may help researchers understand what drives cancer activity and immune responses, which could guide better treatments in the future.
Victoria, British ColumbiaAges 18 years+ - NCT05027633RecruitingPhase 2
Immunotherapy plus chemo and radiation for nasal cancer
This Phase 2 study tests a treatment plan that combines immunotherapy with chemotherapy and chemoradiation for advanced squamous cell cancer in the nasal cavity or sinuses. It aims to improve cancer control in people who are newly diagnosed and have not had prior treatment for this cancer.
Houston, TexasAges 18 years+ - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT05029791Recruiting
Study of immune markers in treated metastatic melanoma
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
LyonAges 18 years+ - NCT05030597Recruiting
PET scans targeting FAP for oral cancer and recurrence
This trial uses a special PET scan that targets a substance called FAP to better find oral squamous cell cancer and check for recurrence. It may help doctors see where cancer activity is and guide treatment planning, especially around surgery and (for some people) neoadjuvant therapy before surgery.
Wuhan, HubeiAges 18–70 - NCT05031910Recruiting
Virtual 3D guidance for head and neck cancer surgery
This study tests whether a virtual reality (3D computer) model of surgery can help surgeons improve how head and neck cancer operations are planned and done. You may benefit from more personalized surgical planning, if you’re eligible for standard surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05030805Recruiting
Study maps ovarian cancer cells from surgical tissue
This study uses lab testing to create a “map” of ovarian cancer cells one cell at a time, to better understand the disease. It likely helps researchers learn which cell types are involved, using samples collected around your surgery.
Strasbourg, AlsaceAges 18–80 - NCT05040555Recruiting
Testing a new chemo plan for newly diagnosed high-burden lymphoma
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
Changchun, JilinAges 18–75 - NCT05041140Recruiting
Xenon MRI test for lung problems after stem cell transplant
This study uses a special MRI test with xenon gas to look at lung function in adults who had a stem cell transplant and now have breathing-related complications. It may help doctors measure lung impairment more clearly and track changes over time.
Houston, TexasAges 18 years+ - NCT05044117RecruitingPhase 3
Capecitabine pills after chemoradiation for head and neck cancer
This trial tests whether taking capecitabine pills on a steady, low schedule after standard treatment can help keep locally advanced head and neck squamous cell cancer from coming back or spreading. You may be eligible if your cancer is stage III–IV and you have finished certain radiation/chemo treatments on time, without current spread.
Guangzhou, GuangdongAges 18–70 - NCT05049538Recruiting
Liquid blood tests to predict endometrial cancer return
This trial studies whether blood “liquid biopsies” and tumor genetic testing can help predict whether endometrial cancer will come back after treatment. Results may help doctors plan follow-up and additional care based on a person’s recurrence risk.
Houston, TexasAges 18 years+ - NCT05052957RecruitingPhase 2
Autologous stem cell rescue for newly diagnosed brain tumor
This trial tests giving a patient’s own stem cells back to help the bone marrow recover after treatment for newly diagnosed glioblastoma or gliosarcoma. It may help reduce blood-count problems so treatment can be given more safely.
Cleveland, OhioAges 18–75 - NCT05054413Recruiting
Expert guideline survey for prostate cancer care
This study uses a structured expert survey to help build clear, agreed-upon guidelines for prostate cancer care. If you’re a board-certified clinician who actively treats prostate cancer, your input can help shape how care is recommended.
Houston, TexasAges 21 years+ - NCT05059951Recruiting
Chemotherapy With or Without Immunotherapy for Lung Cancer
This trial looks at whether adding an immunotherapy drug (an immune checkpoint inhibitor) to chemotherapy helps people with lung cancer live better or respond better. You might be considered if your cancer is confirmed, you can tolerate treatment, and imaging shows measurable spots.
Changsha, HunanAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,686 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.